News
Paralysis treatment heals lab-grown human spinal cord organoids
February 11, 2026
In a new study, Northwestern University scientists used lab-grown human spinal cord organoids — miniature organs derived from stem cells — to model different types of spinal cord injuries and test a promising new regenerative therapy.
Northwestern University researchers develop STP to protect the brain after stroke
January 8, 2026
Northwestern University researchers led by Ayush Batra and Samuel Stupp published a study describing a supramolecular therapeutic peptide (STP) that protects the brain after ischemic stroke. In a mouse model, the therapy crossed the blood-brain barrier and significantly reduced brain damage.
Amphix Bio awarded grant from Reeve Foundation and Spinal Research
January 6, 2026
Amphix Bio has received a research grant to test AMFX-200, the company’s lead Supramolecular Therapeutic Peptide (STP) candidate, in combination with structured physical rehabilitation in both acute and chronic spinal cord injury models.
Amphix Bio raises $12.5M seed round to advance peptide drug platform
December 18, 2025
Amphix Bio announced the initial closing of a $12.5 million seed financing round to advance its lead therapeutic candidates toward human clinical trials and expand its pipeline to target additional neurological conditions.
Amphix Bio receives FDA Orphan Drug Designation for acute spinal cord injury therapeutic
July 16, 2025
The U.S. Food and Drug Administration (FDA) has granted an Orphan Drug Designation to AMFX-200, Amphix Bio's lead candidate for the treatment of acute spinal cord injury.
Amphix Bio lands federal and state grants to manufacture regenerative therapies
October 31, 2024
Amphix Bio announced that it has secured a $1M Small Business Innovation Research (SBIR) Phase II grant from the National Science Foundation to scale up manufacturing methods for its platform technology of supramolecular peptide therapeutics.
FDA grants Breakthrough Device designation to Amphix Bio’s bone regeneration product
October 3, 2024
Amphix Bio announced today it has received a Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for a drug-device combination product for bone regeneration.
New biomaterial repairs damaged cartilage in sheep model
August 5, 2024
Northwestern University scientists have developed a new bioactive material that successfully regenerated high-quality hyaline cartilage in the knee joints of sheep.
Stupp Lab uses supramolecular therapeutics platform to grow cartilage
July 26, 2024
Professor Samuel Stupp's group at Northwestern University published work demonstrating that supramolecular motion is a key factor in biological signaling for cartilage regeneration. Stupp is the co-founder and Chief Scientific Officer of Amphix Bio.
Regenerative nanomaterial enables spinal fusion with minimal growth factor
October 17, 2023
Scientists at Northwestern University published a new study describing a novel therapeutic for bone regeneration that induced spinal fusion with a 100-fold dose reduction in recombinant BMP-2 compared to current clinical products.
Amphix Bio secures SBIR award to advance regenerative technology for spinal fusion
February 24, 2022
Amphix Bio has received a Small Business Innovation Research (SBIR) Phase I grant from the National Science Foundation to advance a new bone regeneration technology for treating debilitating back pain caused by degenerative disc disease.
Videos
Amphix Bio co-founder Samuel Stupp was featured in more than 350 news stories after his laboratory published research on an injectable therapeutic for spinal cord injury. Watch the video packages below from Northwestern University and BBC News to learn more about this research.